NHDL, a recombinant VL/VH hybrid antibody control for IgG2/4 antibodies

NHDL, a recombinant VL/VH hybrid antibody control for IgG2/4 antibodies

The mechanism of action of recombinant IgG2/4 antibodies involves blocking of their target without the induction of effector functions. Examples are eculizumab (Soliris®), which is used clinically to block complement factor C5, as well as anti-human CD14 (r18D11) and anti-porcine CD14 (rMIL2) produc...

Full description

Bibliographic Details
Main Authors: Corinna Lau, Martin Berner McAdam, Grethe Bergseth, Algirdas Grevys, Jack Ansgar Bruun, Judith Krey Ludviksen, Hilde Fure, Terje Espevik, Anders Moen, Jan Terje Andersen, Tom Eirik Mollnes
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:mAbs
Subjects:
Recombinant antibody
control antibody
IgG2/4
hybrid
therapeutic antibody
Online Access:https://www.tandfonline.com/doi/10.1080/19420862.2019.1686319

Internet

https://www.tandfonline.com/doi/10.1080/19420862.2019.1686319

Similar Items